| pubmed-article:10880506 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C0035687 | lld:lifeskim |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C0001752 | lld:lifeskim |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C0005456 | lld:lifeskim |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C1419989 | lld:lifeskim |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C0086222 | lld:lifeskim |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C1283195 | lld:lifeskim |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C0520986 | lld:lifeskim |
| pubmed-article:10880506 | lifeskim:mentions | umls-concept:C1705733 | lld:lifeskim |
| pubmed-article:10880506 | pubmed:issue | 37 | lld:pubmed |
| pubmed-article:10880506 | pubmed:dateCreated | 2000-10-13 | lld:pubmed |
| pubmed-article:10880506 | pubmed:abstractText | Splicing of the last intron (intron D) of the bovine growth hormone pre-mRNA requires the presence of a downstream exonic splicing enhancer (ESE). This enhancer is contained within a 115-nucleotide FspI-PvuII (FP) fragment located in the middle of the last exon (exon 5). Previous work showed that the splicing factor SF2/ASF binds to this FP region and stimulates splicing of intron D in vitro. However, the precise sequences recognized by SF2/ASF within the FP region had not been determined. Here we used multiple strategies to map the SF2/ASF binding sites and determine their importance for ESE function. Taking advantage of the fact that SF2/ASF ultraviolet (UV) cross-links specifically to RNA containing the FP sequence, we first mapped a major SF2/ASF binding site by UV cross-linking and reverse transcription. This strategy identified a 29-nucleotide SF2/ASF binding region in the middle of the FP sequence containing the 7-nucleotide purine-rich motif described previously. Interestingly, this binding region is neither sufficient, nor absolutely required for SF2/ASF-mediated splicing, suggesting that additional SF2/ASF binding sites are present. The location of these additional sites was determined by electrophoretic mobility shift analysis of various subfragments of the FP sequence. Antisense 2'-O-methyl oligoribonucleotides complementary to selected SF2/ASF binding sites block bovine growth hormone intron D splicing. Thus, multiple SF2/ASF binding sites within the exonic splicing enhancer contribute to maximal enhancer activity. | lld:pubmed |
| pubmed-article:10880506 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10880506 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10880506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10880506 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10880506 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10880506 | pubmed:issn | 0021-9258 | lld:pubmed |
| pubmed-article:10880506 | pubmed:author | pubmed-author:RottmanF MFM | lld:pubmed |
| pubmed-article:10880506 | pubmed:author | pubmed-author:LULL | lld:pubmed |
| pubmed-article:10880506 | pubmed:author | pubmed-author:KrainerA RAR | lld:pubmed |
| pubmed-article:10880506 | pubmed:author | pubmed-author:MayedaAA | lld:pubmed |
| pubmed-article:10880506 | pubmed:author | pubmed-author:DirksenW PWP | lld:pubmed |
| pubmed-article:10880506 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10880506 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:10880506 | pubmed:volume | 275 | lld:pubmed |
| pubmed-article:10880506 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10880506 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10880506 | pubmed:pagination | 29170-7 | lld:pubmed |
| pubmed-article:10880506 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:meshHeading | pubmed-meshheading:10880506... | lld:pubmed |
| pubmed-article:10880506 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10880506 | pubmed:articleTitle | Mapping the SF2/ASF binding sites in the bovine growth hormone exonic splicing enhancer. | lld:pubmed |
| pubmed-article:10880506 | pubmed:affiliation | Department of Molecular Biology and Microbiology and the Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106-4960, USA. | lld:pubmed |
| pubmed-article:10880506 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10880506 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10880506 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10880506 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10880506 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10880506 | lld:pubmed |
